Status:
UNKNOWN
Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China
Lead Sponsor:
Southeast University, China
Conditions:
Critically Ill
Anti-Xa
Eligibility:
All Genders
18+ years
Brief Summary
Critically ill Patients are at high risk to develop deep venous thrombosis. However, despite receiving of a standard dose of Low-molecular-weight Heparin（LMWH）, many patients still develop life-threat...
Eligibility Criteria
Inclusion
- Adult Critically ill patients
Exclusion
- Contraindication to use of LMWH. Intracranial bleeding/stroke, hematoma or bleeding disorder. Use Heparin anticoagulant therapy
Key Trial Info
Start Date :
August 15 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 30 2018
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03311984
Start Date
August 15 2017
End Date
May 30 2018
Last Update
October 17 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Changde Wu
Nanjing, Jiangsu, China, 210029